Skip to content
Large group of approximately 30 diverse individuals stand in front of Indonesian architectural statue smiling into camera.

Community Advocates

Communities affected by TB have the most at stake when new vaccines arrive, and the strongest voice in how they are introduced. Preparing now means sharing information, answering questions, and getting ahead of misinformation and disinformation before vaccines are available. Here you will find conversation starters, key messages, and quick facts to help you talk with neighbors, community leaders, and government decision makers about why the world needs new TB vaccines, and what it will take to make sure everyone who needs them can benefit.

Filter

Developed in honor of World TB Day 2026, this zine demystifies vaccines, TB, and leading TB vaccine candidates. Tapping into optimism for a future TB vaccine and the importance of community care through vaccination, this zine grounds the conversation in what an effective new TB vaccine would look like for communities, how vaccines integrate into the larger TB prevention strategy, and how a new TB vaccine for adults and adolescents could be a powerful tool in the quest to end TB. 

A Shot at Success: A Vax-Zine on New Tuberculosis Vaccines Thumbnail
Treatment Action Group (TAG)

A Shot at Success: A Vax-Zine on New Tuberculosis Vaccines

A colorful, visual guide to understanding and navigating TB vaccines, the pipeline, and the potential impact of a new TB vaccine on the effort to end TB.

The research process from discovery to clinical trials to implementation can be opaque making interpreting results from studies difficult for even a seasoned researcher or activist. This lecture series walks through the fundamentals of research, key terms, and common measures found in clinical trial results; preparing activists and advocates to understand TB vaccine trial results as they emerge over the next several years. 

Research Fundamentals for Activists Thumbnail
Treatment Action Group (TAG)

Research Fundamentals for Activists

This lecture provides a crash course on clinical research to support activists and advocates understanding of emerging clinical trial results.

TB has plagued humanity for nearly as long as humanity existed. This lecture offers a broad overview of how TB interacts with the human body and society. Covering everything from the TB bacterium itself, to how the immune system responds to TB, how infection becomes TB disease, and even how TB intersects with larger health and societal disparities, this module dives into why TB remains so persistent over the centuries despite our best efforts to end TB.  

TB Basics Crash Course Thumbnail
Treatment Action Group (TAG)

TB Basics Crash Course

This lecture covers the basics of TB, how it interacts with the body, its global prevalence, and drivers behind TB's persistance in the 21st century.

This cheat sheet designed specifically for community activists gives readers a high level overview of the basic science behind different common vaccine types (i.e., mRNA vaccines, viral vector vaccines). The vaccine types included all represent types of vaccines under development for the TB and the cheat sheet provides examples of well known vaccines for other diseases that use a similar design model. The cheats sheet notes key considerations that influence the efficacy, safety, acceptance, and accessibility of vaccines.

TB Vaccines Cheat Sheet for Tuberculosis Advocates Thumbnail
Treatment Action Group (TAG)

TB Vaccines Cheat Sheet for Tuberculosis Advocates

This cheat sheet walks through different vaccine types under development for TB, comparing the benefits and downsides of each approach.

Over one hundred years after the introduction of BCG, the TB Vaccine Pipeline holds the potential for a new TB vaccine.  This crash course covers the history, immunology and science behind the development of TB vaccines, and covers the major developments that lead to the opening of recent phase III trials. 

TB Vaccines Crash Course Thumbnail
Treatment Action Group (TAG)

TB Vaccines Crash Course

This lecture covers the science, immunology, and history behind TB vaccines and what potential new vaccines mean for TB prevention.

The Working Group on New TB Vaccines TB Vaccine Pipeline covers TB vaccine candidates from preclinical proof-of-concept models to post-marketing studies. Candidates for each category can be viewed by latest stage of development, or on a sortable page that filters candidates by certain categories. Follow the pipeline as candidates move along the development pathway towards the goal of entering Phase III trials. 

Working Group on New TB Vaccines TB Vaccine Pipeline Thumbnail
Working Group on New TB Vaccines (WGNV)

Working Group on New TB Vaccines TB Vaccine Pipeline

The TB Vaccine Pipeline explores vaccine candidates from preclinical proof-of-concept models to post-marketing studies to see where the TB vaccine field is advancing.

The long awaited results from the PreVenTB trial of two candidate TB vaccines — VPM1002 and Immuvac — were disappointing for the vaccine candidates themselves, but represented a victory for TB vaccine science and community engagement. 

Civil society and communities celebrated that the PreVenTB trials represented the largest TB vaccine trial of this century and was funded by high-TB-burden country governments. Further the study was designed to reflect the specific epidemiology of the TB epidemic within India, enrolling populations that stand to benefit the most from a future TB vaccine but were left out of other trials. 

TAG Statement on Results of the PreVenTB Phase III Trial of TB Vaccine Candidates VPM1002 and Immuvac Thumbnail
Treatment Action Group (TAG)

TAG Statement on Results of the PreVenTB Phase III Trial of TB Vaccine Candidates VPM1002 and Immuvac

This statement digests and interprets the disappointing results from the VPM1002 vaccine candidate's phase III trial in adults and adolescents.

What Could Go Right? Vital Partnerships with Communities and Civil Society for New Tuberculosis Vaccines, explores the foundational role that community and civil society groups can play in the successful introduction of a new TB vaccine and strategies for capacitating and empowering communities towards that goal. In bringing together three unique sub-studies, this first-of-its-kind report examines community and civil society’s readiness to engage in TB vaccine advocacy and policymaking at national, regional, and global levels, and underscores the transformative role communities can play in TB vaccine introduction, as well as the critical need for other stakeholders to help them realize that potential.

Webinar | What Could Go Right? Partnering with Communities and Civil Society for New TB Vaccines Thumbnail
Treatment Action Group (TAG)

Webinar | What Could Go Right? Partnering with Communities and Civil Society for New TB Vaccines

This webinar discusses the What Could Go Right? report and the path forward to capacitating and engaging community and civil society in the preparation for and introduction of a future TB vaccine.

Intermediate

Treatment Action Group’s 2026 Tuberculosis Vaccines Pipeline Report surveys major developments in the clinical development of new TB vaccines at this moment of scientific promise and political peril. The pipeline contains 14 candidates and covers vaccines that currently in Phase I, II, or III trials,  For each candidate, TAG summarizes the known ongoing, recently completed, or planned clinical trials. Narrative descriptions throughout discuss the notable updates of key candidates that generated the most news over the past year either due to clinical trial results, delays, or the beginning of major new studies.

2026 Tuberculosis Vaccine Pipeline Report Thumbnail
Treatment Action Group (TAG)

2026 Tuberculosis Vaccine Pipeline Report

TAG's annual pipeline reports summarizes movement in the TB vaccine field including known ongoing, recently completed or planned clinical trials on TB vaccine candidates.

As now-late stage TB vaccine candidates were quietly advancing through the Pipeline, the World Health Organization brought together a group of scientists, developers, funders, civil society, and community representatives to discuss the ideal characteristics of a future TB vaccine. This document presents the preferred characteristics for new TB vaccines, informed by the high need for additional vaccines to meaningfully shift the battle to end TB. 

The overarching priorities underscore the need for a vaccine to prevent pulmonary TB and reduce transmission of TB in adults and adolescents alongside a new pediatric vaccine that improves on the safety and efficacy of BCG. 

WHO Preferred Product Characteristics for New Tuberculosis Vaccine Thumbnail
World Health Organization (WHO)

WHO Preferred Product Characteristics for New Tuberculosis Vaccine

Informed by the high need for new TB vaccines to support the fight to end TB, the World Health Organization's Preferred Product Characteristics outlines priority characteristics for TB vaccines in the short-term.

Back To Top